RESUMO
Functionalization of metal-organic frameworks (MOFs) is critical in exploring their structural and chemical diversity for numerous potential applications. Herein, we report multiple approaches for the tandem postsynthetic modification (PSM) of various MOFs derived from Zr(IV), Al(III), and Zn(II). Our current work is based on our efforts to develop a wide range of MOF platforms with a dynamic functional nature that can be chemically switched via thermally triggered reversible Diels-Alder (DA) and hetero-Diels-Alder (HDA) ligations. Furan-tagged MOFs (furan-UiO-66-Zr) were conjugated with maleimide groups bearing dienophiles to prepare MOFs with a chemically switchable nature. As HDA pairs, phosphoryl dithioester-based moieties and cyclopentadiene (Cp)-grafted MOF (Cp-MIL-53-Al) were utilized to demonstrate the cleavage and rebonding of the linkages as a function of temperature. In addition to these strategies, the Michael addition reaction was also applied for the tandem PSM of IRMOF-3-Zn. Maleimide groups were postsynthetically introduced in the MOF lattice, which were further ligated with cysteine-based biomolecules via the thiol-maleimide Michael addition reaction. On the basis of the versatility of the herein presented chemistry, we expect that these approaches will help in designing a variety of sophisticated functional MOF materials addressing diverse applications.
RESUMO
Development of low cost biosensing using convenient and environmentally benign materials is important for wide adoption and ultimately improved healthcare and sustainable development. Immobilized antibodies are often incorporated as an essential biorecognition element in point-of-care biosensors but these proteins are costly. We present a strategy of combining convenient and low-cost surface functionalization approaches for increasing the overall binding activity of antibody functionalized natural and synthetic fibers. We demonstrate a simple one-step in situ silica NP growth protocol for increasing the surface area available for functionalization on cotton and polyester fabrics as well as on nanoporous cellulose substrates. Comparing this effect with the widely adopted and low cost plant-based polyphenol coating to enhance antibody immobilization, we find that both approaches can similarly increase overall surface activity, and we illustrate conditions under which the two approaches can produce an additive effect. Furthermore, we introduce co-immobilization of antibodies with a sacrificial "steric helper" protein for further enhancing surface activities. In combination, several hundred percent higher activities compared to physical adsorption can be achieved while maintaining a low amount of antibodies used, thus paving a practical path towards low cost biosensing.
RESUMO
Targeting bioactives selectively to diseased sites is one of the most challenging aspects of cancer therapy. Herein, fabrication of colonic enzyme-responsive dextran based oligoester crosslinked nanoparticles is reported for the controlled release of 5-fluorouracil (5-FU) - an anticancer drug. The 5-FU drug loaded nanoparticles (DNPs, size ~237 ± 25 nm, ζ-potential -17.0 ± 3 mV) were developed by the in-situ crosslinking of dextran with a bifunctional telechelic oligoester followed by the physical drug encapsulation via nanoprecipitation. Drug encapsulation efficiency and drug loading capacity of DNPs were found to be ~76% (±0.1) and ~8% (±0.1), respectively. The DNPs were demonstrated to release the encapsulated drug selectively in the presence of dextranase enzyme. The in vitro release kinetics assay revealed that the DNPs released about 75% (±4) of the entrapped drug within 12 h of incubation with dextranase enzyme. No drug was released in a control experiment where DNPs were exposed to pH conditions encountered in the stomach and small intestine. Moreover, the treatment of HCT116 colon cancer cell line with the developed DNPs highlighted its biocompatibility as well as dextranase triggered cytotoxicity. The developed system offers an avenue to reduce the non-specific cytotoxicity of the encapsulated 5-FU, and a colon specific delivery of the encapsulated drug in response to the dextranase enzyme.
